<DOC>
	<DOCNO>NCT01375465</DOCNO>
	<brief_summary>The 001 DIOR study prospective , multicenter registry percutaneous coronary intervention ( PCI ) assess clinical success , efficacy safety Paclitaxel-eluting balloon DIOR ( Eurocor GmbH , Germany ) treatment de novo ostial bifurcate lesion ( 001 Medina classification ) . The DIOR balloon use treat stenotic site branch .</brief_summary>
	<brief_title>The 001-DIOR Multicenter Registry</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>De novo bifurcate lesion 001 Medina classification , significant stenosis ostium side branch reference vessel diameter big equal 2.0mm ; DIOR balloon use treat side branch . The patient clinical evidence myocardial ischemia ( stable unstable angina , acute non acute myocardial infarction , silent ischemia : ECG , exercise test , etz ... ) As maximal length DIORTM balloon 30 mm , eligible lesion longer 25 mm ensure adequate drug elution treat segment , avoid phenomenon `` geographical miss '' . Target lesion ( ) stenosis equal 50 % visual estimation . Cardiogenic shock Any serious disease might limit patient survival less one year Inability perform clinical followup period 1 year Left main bifurcation lesion : ostial leave circumflex ostial leave anterior descend artery stenosis . Lesion length &gt; 25 mm Target vessel reference diameter &lt; 2mm Stenosis &lt; 50 % reference luminal diameter Severe angiographic calcification level target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>